Current studies into retatrutide, a dual stimulant for GLP-1 and GIP receptors, are demonstrating encouraging results in managing excess mass and type 2 condition. Preclinical evidence suggest a unique mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/